AssetMark Inc
BIIB icon

AssetMark Inc’s Biogen BIIB Stock Holding History

AssetMark Inc’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$548K Sell
2,535
-155
-6% -$29.6K ﹤0.01% 1209
2026
Q1 		$493K Buy
2,690
+298
+12% +$54.9K ﹤0.01% 1163
2025
Q4 		$421K Buy
2,392
+321
+15% +$52.4K ﹤0.01% 1160
2025
Q3 		$290K Buy
2,071
+390
+23% +$52.7K ﹤0.01% 1187
2025
Q2 		$211K Buy
1,681
+1,586
+1,669% +$198K ﹤0.01% 1209
2025
Q1 		$13K Sell
95
-13
-12% -$1.86K ﹤0.01% 1795
2024
Q4 		$16.5K Buy
108
+79
+272% +$13.3K ﹤0.01% 1697
2024
Q3 		$5.62K Sell
29
-448
-94% -$93.7K ﹤0.01% 1717
2024
Q2 		$111K Sell
477
-4,520
-90% -$982K ﹤0.01% 1093
2024
Q1 		$1.08M Sell
4,997
-38
-0.8% -$8.9K ﹤0.01% 715
2023
Q4 		$1.3M Buy
5,035
+161
+3% +$39.5K ﹤0.01% 620
2023
Q3 		$1.25M Buy
4,874
+411
+9% +$110K 0.01% 581
2023
Q2 		$1.27M Buy
4,463
+2,040
+84% +$607K 0.01% 563
2023
Q1 		$674K Buy
2,423
+367
+18% +$102K ﹤0.01% 669
2022
Q4 		$569K Buy
2,056
+528
+35% +$149K ﹤0.01% 685
2022
Q3 		$408K Buy
1,528
+434
+40% +$92.2K ﹤0.01% 683
2022
Q2 		$223K Buy
1,094
+622
+132% +$127K ﹤0.01% 730
2022
Q1 		$99K Sell
472
-349
-43% -$75.9K ﹤0.01% 791
2021
Q4 		$197K Buy
821
+87
+12% +$22.4K ﹤0.01% 701
2021
Q3 		$208K Sell
734
-63,735
-99% -$20.9M ﹤0.01% 566
2021
Q2 		$22.3M Sell
64,469
-152,762
-70% -$46.3M 0.1% 175
2021
Q1 		$60.8M Sell
217,231
-26,055
-11% -$7.03M 0.31% 90
2020
Q4 		$59.6M Buy
243,286
+15,165
+7% +$3.91M 0.33% 83
2020
Q3 		$64.7M Buy
228,121
+17,504
+8% +$4.88M 0.42% 70
2020
Q2 		$55.7M Buy
210,617
+209,925
+30,336% +$63.1M 0.4% 65
2020
Q1 		$219K Buy
692
+430
+164% +$130K ﹤0.01% 481
2019
Q4 		$78K Sell
262
-97
-27% -$26.9K ﹤0.01% 659
2019
Q3 		$84K Buy
359
+45
+14% +$10.5K ﹤0.01% 634
2019
Q2 		$73K Sell
314
-74
-19% -$17.1K ﹤0.01% 647
2019
Q1 		$92K Sell
388
-57
-13% -$17.9K ﹤0.01% 594
2018
Q4 		$134K Buy
445
+80
+22% +$25.5K ﹤0.01% 504
2018
Q3 		$129K Sell
365
-61
-14% -$21K ﹤0.01% 533
2018
Q2 		$124K Buy
426
+11
+3% +$3.09K ﹤0.01% 530
2018
Q1 		$114K Sell
415
-7,922
-95% -$2.46M ﹤0.01% 555
2017
Q4 		$2.66M Buy
8,337
+7,948
+2,043% +$2.55M 0.03% 243
2017
Q3 		$122K Buy
389
+63
+19% +$18.7K ﹤0.01% 537
2017
Q2 		$88K Sell
326
-1
-0.3% -$264 ﹤0.01% 568
2017
Q1 		$89K Buy
327
+10
+3% +$2.83K ﹤0.01% 533
2016
Q4 		$90K Sell
317
-98
-24% -$29.1K ﹤0.01% 519
2016
Q3 		$130K Buy
415
+39
+10% +$11.6K ﹤0.01% 458
2016
Q2 		$91K Sell
376
-2,108
-85% -$556K ﹤0.01% 500
2016
Q1 		$646K Buy
2,484
+88
+4% +$23.2K 0.01% 306
2015
Q4 		$734K Buy
2,396
+2,156
+898% +$620K 0.01% 321
2015
Q3 		$70K Buy
240
+160
+200% +$52.8K ﹤0.01% 368
2015
Q2 		$32K Buy
+80
New +$32.1K ﹤0.01% 438

Other funds holding BIIB

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ADEF
Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

AssetMark Inc's BIIB Position: Q2 2026 in Review

AssetMark Inc reduced its Biogen (BIIB) stake by 5.8% in Q2 2026, selling an estimated $29.6K and leaving 2,535 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #1209.

AssetMark Inc first reported a position in BIIB in Q2 2015 and has held it in 45 quarters since. The position peaked at $64.7M in Q3 2020. 405 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • AssetMark Inc held 2,535 shares of Biogen worth $548K as of Q2 2026.
  • AssetMark Inc sold 155 Biogen shares in Q2 2026, an estimated $29.6K.
  • Biogen made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1209 holding.
  • AssetMark Inc first reported a position in Biogen in Q2 2015 and has held it in 45 quarters since.
  • AssetMark Inc's Biogen position peaked at $64.7M in Q3 2020.
  • 405 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.